HCC1806細胞
細胞形態： 上皮樣
運輸方式： 凍存運輸
生長狀態： 貼壁生長
數量： 大量
是否是腫瘤細胞： 1
物種來源： 人
年限： TNM stage IIB, grade 2
ATCC Number： CRL-2335?
器官來源： **
相關**： 其他**
Designations: HCC1806
Depositors: AF Gazdar, AK Virmani
HCC1806細胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent, The line grows as attached medium-sized epithelial cells without floating cells.
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: mammary gland; breast
Tumor Stage: TNM stage IIB, grade 2
Disease: primary acantholytic squamous cell carcinoma
Cellular Products: Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. HCC1806細胞Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Applications: The cells are poorly differentiated.
HCC1806 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).
The cells are negative for expression of Her2-neu and for expression of p53.
Receptors: estrogen receptor, negative
progesterone receptor, negative
Oncogene: her2/neu -, p53 -
Cytogenetic Analysis: Number of cells examined = 59; Modal Chromosome Number = 75 with a range of 65 to 79; Polyploidy Rate = 22%
Age: 60 years
Gender: female
Ethnicity: Black
Comments: HCC1806細胞The HCC1806 cell line was initiated on July 31, 1995, and took 10 months to establish.
The tumor was classified as a TNM Stage IIB, grade 2, acantholytic squamous carcinoma with no lymph node metastasis.
There was no family history of breast cancer.
The cells are poorly differentiated.
The cells are negative for expression of Her2-neu and for expression of p53.
HCC1806 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).
The cells are homozygous for deletions in the FHIT gene at 3p14.2.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, rinse with 0.25% trypsin, 0.03% EDTA solution, add an additional 1 to 2 ml of trypsin solution and allow the flask to set at room temperature (or incubate at 37C) until cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 32258: HCC1806細胞Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768
38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
